Detecção de anticorpos anti-VCA do vírus Epstein-Barr em pacientes HIV-Positivos com e sem Leucoplasia Pilosa oral no Serviço de Doenças Infecciosas e Parasitárias do Hospital Universitário Antônio Pedro

• Ano de defesa: 2005
• Autor(a) principal: Nascimento, Cristiano de Paula
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Programa de Pós-graduação em Patologia; Patologia
• Palavras-chave em Português: Vírus Epstein-Barr; Soroprevalência anti-VCA; Leucoplasia pilosa oral; Detecção de anticorpos anti-VCA do vírus Epstein- Barr em pacientes HIV-positivos com e sem leucoplasia pilosa oral no Hospital Universitário Antônio Pedro; Leucoplasia pilosa; HIV-1; Herpesvírus 4 Humano; Medicina; Patologia experimental; CNPQ::CIENCIAS DA SAUDE::MEDICINA::ANATOMIA PATOLOGICA E PATOLOGIA CLINICA
• Link de acesso: https://app.uff.br/riuff/handle/1/20048

Epstein-Barr virus (EBV) is an ubiquitous herpesvirus envolved in the pathogenesis of oral hairy leukoplakia (OHL), a white lesion inicially decribed on the lateral border of the tongue in acquired immunodefiency syndrome (AIDS) patients. Oral candidiasis and OHL shows high prevalence in human immunodefiency virus-1 (HIV-1) seropositive individuals, since immunosupression during HIV-1 infection favours the onset of opportunistic infections, such as oral lesions, characteristically accompanied by immunosupression. However, despite the association between HIV-1 infection and the presence of OHL in the literature, few studies have correlated serologic profiles of EBV infection with the presence of OHL. The aim of this study was to identify IgG and IgM anti-VCA (viral capsid antigen) levels for recent and latent EBV infection in HIV-1 seropositive individuals with and without OHL and to investigate the correlation between EBV serology and immune status. In order to characterize the EBV-specific serologic responses to IgG and IgM antibodies to the EBV viral capsid antigen (VCA), we studied 44 HIV-1 seropositive patients (22 males and 22 females) referred to the Hospital Universitário Antônio Pedro at the Universidade Federal Fluminense relating to the presence of OHL. EBV serology was determined by enzyme immunoassay (ELISA) and the presence of OHL was diagnosed by cytopathology. Serology was compared to the presence of OHL and immune status (CD4 counts and HIV-1 viral load). 8/44 (18,2%) patients were positive for OHL. For the cohort overall there was no correlation between the presence of OHL and active EBV infection. Therefore all samples were IgG anti-VCA positive, showing that all patients had a typical serologic profile of latent infection with no statistically significant differrences (p>0,05) within IgG anti-VCA levels. These results suggest that OHL is not associated with IgM levels tested by ELISA in the studied population. Besides IgG anti-VCA levels did not differ between patients with or without OHL. However our data point out the need of enrolling a larger group of individuals in order to sustain our findings or not, since there are controversial data in the literature regarding association between EBV serology and the presence of OHL in HIV-1 positive individuals